Kyntra Bio (LTS:0IL8) Loans Receivable: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0IL8 Kyntra Bio Inc LTS:0IL8
53 GF Score
Price $6.83
GF Value $5.56
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Loans Receivable?

Kyntra Bio LTS:0IL8 -2.49% 53 Loans Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates LTS:0IL8 with a GF Score™ of 53/100 and a GF Value™ of $5.56 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Kyntra Bio's Loans Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Kyntra Bio Loans Receivable Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio Loans Receivable Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kyntra Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0IL8
53GF Score
Kyntra Bio Inc LTS:0IL8
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Kyntra Bio (LTS:0IL8) has a Loans Receivable of $0.00 Mil as of Mar. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Kyntra Bio and its competitors.
Is Kyntra Bio's Loans Receivable too high?
Kyntra Bio's current Loans Receivable is $0.00 Mil. Overall, Kyntra Bio has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Loans Receivable compare to ACTU and PLRZ?
Kyntra Bio's Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.56, compared to a current price of $6.83 — trading 22.8% above its estimated fair value. The current Loans Receivable is $0.00 Mil. Kyntra Bio's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current Loans Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of $6.83 is trading 22.8% above its estimated GF Value™ of $5.56. GuruFocus considers Kyntra Bio to be Modestly Overvalued.

Key valuation signals for LTS:0IL8:

  • Loans Receivable: $0.00 Mil
  • GF Value™: $5.56 vs. price of $6.83 (22.8% above fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kyntra Bio Business Description

Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
53GF Score

Get the complete analysis for LTS:0IL8

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.83
Price
$5.56
GF Value